News ArticleGlaxoSmithKline Pharmaceuticals Posts ₹45,758 Lakh Profit Before Tax in Q2 FY2026-27, Names Sandeep Seth Head of Ethics & Compliance
Company approves M/s Walker Chandiok & Co LLP as new statutory auditors for 5-year term starting FY2027-28, subject to member approval
GlaxoSmithKline Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026, revealing a profit before tax of ₹45,758 lakh for Q2. The company also appointed Mr. Sandeep Seth as Head - Ethics & Compliance and approved the appointment of M/s Walker Chandiok & Co LLP as statutory auditors for FY2027-28 to FY2031-32, subject to member approval.
GlaxoSmithKline Pharmaceuticals Limited
General / Other
GlaxoSmithKline Pharmaceuticals Limited reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, posting a profit before tax of ₹45,758 lakh for Q2. Alongside results, the company appointed Mr. Sandeep Seth as Head - Ethics & Compliance and approved the appointment of M/s Walker Chandiok & Co LLP as statutory auditors for a five-year term from FY2027-28 to FY2031-32, pending member approval.
The company recorded a total income of ₹125,268 lakh for Q2 FY2026-27 and ₹223,873 lakh for the half-year period, with total expenses amounting to ₹79,510 lakh in Q2. The net profit after tax for the quarter stood at ₹33,462 lakh.
Mr. Sandeep Seth, who has over 20 years of experience in ethics, compliance, and governance across pharmaceutical and healthcare sectors, was appointed as Head - Ethics & Compliance effective November 3, 2026. He will join the APAC Compliance leadership team and India Leadership Team at GSK Pharma.
The Board also approved appointing M/s Walker Chandiok & Co LLP as statutory auditors for a first term of five years starting FY2027-28, subject to member approval at the upcoming Annual General Meeting. The auditor firm is a reputed chartered accountancy practice registered with ICAI and PCAOB, serving many large listed companies in India.
The Board meeting that approved these decisions commenced at 3:45 p.m. and concluded at 6:00 p.m. on November 3, 2026.
Highlights
- Q2 FY2026-27 profit before tax: ₹45,758 lakh
- H1 FY2026-27 total income: ₹223,873 lakh
- Net profit after tax for Q2: ₹33,462 lakh
- Appointment of Sandeep Seth as Head - Ethics & Compliance from November 3, 2026
- Approved appointment of M/s Walker Chandiok & Co LLP as statutory auditors for FY2027-28 to FY2031-32
- Board meeting date: November 3, 2026
Key Data Snapshot
What happened
- GlaxoSmithKline Pharmaceuticals announced its financial results for Q2 and H1 ended September 30, 2026.
- The company posted a profit before tax of ₹45,758 lakh for Q2 FY2026-27 and a net profit after tax of ₹33,462 lakh.
- Total income for H1 FY2026-27 was recorded at ₹223,873 lakh.
- Mr. Sandeep Seth was appointed as Head - Ethics & Compliance effective November 3, 2026.
- The Board approved M/s Walker Chandiok & Co LLP as statutory auditors for a five-year term starting from FY2027-28, subject to shareholder approval.
Key details
- Mr. Sandeep Seth has over 20 years of experience in ethics, compliance, and governance within pharmaceutical and healthcare sectors.
- He is a qualified lawyer, Certified Compliance Professional, and Certified Fraud Examiner.
- M/s Walker Chandiok & Co LLP is a respected audit firm registered with ICAI and PCAOB, having 99 partners and offices across India.
- The appointment of new statutory auditors is pending approval at the forthcoming Annual General Meeting.
- The Board meeting started at 3:45 p.m. and concluded at 6:00 p.m. on November 3, 2026.
Financial performance
- For Q2 FY2026-27, total income was ₹125,268 lakh comprising revenue from operations and other income.
- Total expenses for Q2 were ₹79,510 lakh, resulting in a profit before exceptional items and tax of ₹45,758 lakh.
- Exceptional item credit of ₹0 lakh was noted.
- The retained earnings and equity share capital remained consistent with prior periods.
- Earnings per share before exceptional items for Q2 were ₹19.76 (basic and diluted).
Highlights
- Q2 FY2026-27 profit before tax: ₹45,758 lakh
- H1 FY2026-27 total income: ₹223,873 lakh
- Net profit after tax for Q2: ₹33,462 lakh
- Appointment of Sandeep Seth as Head - Ethics & Compliance from November 3, 2026
- Approved appointment of M/s Walker Chandiok & Co LLP as statutory auditors for FY2027-28 to FY2031-32
- Board meeting date: November 3, 2026
Disclosures
- SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 - Regulation 30 and 33
- SEBI Circular Nos. CIR/CFD/CMD/41/2015 and List/Comp/14/2018-19
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
